02:47pm Tuesday 19 November 2019

Babraham-US collaboration reveals how injured nerves initiate self-destruction

By unravelling the factors governing axon longevity, this work – supported in the UK by the Biotechnology and Biological Sciences Research Council (BBSRC) and Alzheimer’s Research UK – will increase understanding of both the normal ageing process in nerves and degenerative mechanisms widespread in disease. This breakthrough paves the way for research into new therapies to tackle axon loss in ageing-related conditions like Alzheimer’s Disease.

We lose axons in normal ageing and in neurodegenerative disease but the factors driving this, and whether the mechanisms are related, have until recently remained elusive. This research, reported in Science Express, pinpoints a protein called Sarm1 as having a pivotal role in axon degeneration.

Image: Babraham Institute

Image: Babraham Institute

Sarm1 was originally thought to play a role in the defence of cells against viruses but in an unexpected twist, US collaborators Marc Freeman and colleagues at the University of Massachusetts Medical School found a similar protein in fruit flies that was needed for axons to die. Joint work with Dr Michael Coleman’s team at the Babraham Institute then investigated Sarm1 in mice to confirm this role in mammals. Axons in mice with normal levels of Sarm1 degenerated within hours of injury. Those without Sarm1 survived for over two weeks.

Dr Coleman said, “We’ve already learned a lot about axon degeneration by studying a protein that preserves axons. The problem has been how to apply this in humans – delivering a new protein into a complex nervous system would be extremely challenging. What’s so exciting about this development is that the new protein has to be blocked to protect axons. Inhibiting proteins is the kind of thing that the Pharma industry is particularly good at.”

In Alzheimer’s disease, axons begin to deteriorate at an early stage, and finding ways of keeping them intact to keep brain cells communicating is a key goal for researchers. Dr Eric Karran, Director of Research at Alzheimer’s Research UK, said, “We’re pleased to have supported this study, which has revealed a fundamental mechanism involved in axonal degeneration. More work is still needed to build on this progress and to help determine how the mechanism might be manipulated in the search for treatments for diseases where axonal damage is an important component. Alzheimer’s is the most common cause of dementia, which affects 820,000 people in the UK, and we urgently need to find new treatments if we are to tackle this growing crisis – that means investing in studies like this.”

The team now want to discover whether Sarm1 plays a role in Alzheimer’s disease, and whether drugs developed to target the protein could keep axons working for longer as the disease takes hold, potentially helping delay the onset of symptoms. It’s also hoped that a better understanding of Sarm1’s functions could open up new avenues for protecting against the loss of axons as part of the normal ageing process. Crucially, the researchers suggest that simply preserving axons during normal ageing could also benefit people with Alzheimer’s, by providing extra ‘cognitive reserve’ and helping the brain to resist damage caused by the disease.

Professor Michael Wakelam, Director of The Babraham Institute, which receives strategic funding from the BBSRC, said, “In an ageing population, it is vital to understand the process of normal ageing and to ensure that this new knowledge is applied to age-related disease. These exciting results are important for both. Babraham’s research supported by BBSRC has a focus on understanding healthy ageing and the Institute’s role in this study shows how we can maximise the impact of this fundamental work by partnering with charities such as Alzheimer’s Research UK”.

The research conducted at the Babraham Institute, which undertakes international quality life sciences research to generate new knowledge of biological mechanisms underpinning ageing, development and the maintenance of health, was supported by a strategic grant from the Biotechnology and Biological Sciences Research Council (BBSRC) and an Alzheimerʼs Research UK Grant.


About the Babraham Institute

The Babraham Institute, which receives strategic funding (£22.4M in 2010-11) from the Biotechnology and Biological Sciences Research Council (BBSRC), undertakes international quality life sciences research to generate new knowledge of biological mechanisms underpinning ageing, development and the maintenance of health. The Institute’s research provides greater understanding of the biological events that underlie the normal functions of cells and the implication of failure or abnormalities in these processes. Research focuses on signalling and genome regulation, particularly the interplay between the two and how epigenetic signals can influence important physiological adaptations during the lifespan of an organism. By determining how the body reacts to dietary and environmental stimuli and manages microbial and viral interactions, we aim to improve wellbeing and healthier ageing. www.babraham.ac.uk


BBSRC invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond.

Funded by Government, and with an annual budget of around £445M (2011-2012), we support research and training in universities and strategically funded institutes. BBSRC research and the people we fund are helping society to meet major challenges, including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals.

For more information about BBSRC, our science and our impact see: www.bbsrc.ac.uk.
For more information about BBSRC strategically funded institutes see: www.bbsrc.ac.uk/institutes.

External contact

Dr Claire Cockcroft, Head of External Relations, Babraham Institute

tel: 01223 496260
mob: 01223 496260
fax: 07786 335978

Dr Michael Coleman, Group Leader, Babraham Institute

tel: 01223 496315


Mike Davies, Media Officer

tel: 01793 414694
fax: 01793 413382

Tracey Jewitt, Media Officer

tel: 01793 413355
fax: 01793 413382

Rob Dawson, Head of News

tel: 01793 413204

Share on:

MORE FROM Brain and Nerves

Health news